Your browser doesn't support javascript.
loading
Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
Takuya Sekine; Andre Perez-Potti; Olga Rivera-Ballesteros; Kristoffer Straling; Jean-Baptiste Gorin; Annika Olsson; Sian Llewellyn-Lacey; Habiba Kamal; Gordana Bogdanovic; Sandra Muschiol; David J Wulliman; Tobias Kammann; Johanna Emgard; Tiphaine Parrot; Elin Folkesson; Olav Rooyackers; Lars I Eriksson; Anders Sonnerborg; Tobias Allander; Jan Albert; Morten Nielsen; Jonas Klingstrom; Sara Gredmark-Russ; Niklas K Bjorkstrom; Johan K Sandberg; David A Price; Hans-Gustaf Ljunggren; Soo Aleman; Marcus Buggert; - Karolinska COVID-19 Study Group.
Afiliação
  • Takuya Sekine; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Andre Perez-Potti; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Olga Rivera-Ballesteros; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Kristoffer Straling; Division of Infectious Diseases, Karolinska University Hospital and Department of Medicine Huddinge, Stockholm, Sweden.
  • Jean-Baptiste Gorin; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Annika Olsson; Division of Infectious Diseases, Karolinska University Hospital and Department of Medicine Huddinge, Stockholm, Sweden.
  • Sian Llewellyn-Lacey; Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, UK.
  • Habiba Kamal; Division of Infectious Diseases, Karolinska University Hospital and Department of Medicine Huddinge, Stockholm, Sweden.
  • Gordana Bogdanovic; Dept of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
  • Sandra Muschiol; Dept of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
  • David J Wulliman; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Tobias Kammann; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Johanna Emgard; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Tiphaine Parrot; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Elin Folkesson; Division of Infectious Diseases, Karolinska University Hospital and Department of Medicine Huddinge, Stockholm, Sweden.
  • Olav Rooyackers; Department of Clinical Interventions and Technology, Karolinska Institutet, Stockholm, Sweden. Function Perioperative Medicine and Intensive Care, Karolinska Un
  • Lars I Eriksson; Function Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden. Department of Physiology and Pharmacology, Karolinska Ins
  • Anders Sonnerborg; Division of Infectious Diseases, Karolinska University Hospital and Department of Medicine Huddinge, Stockholm, Sweden. Division of Clinical Microbiology, Depar
  • Tobias Allander; Dept of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden. Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sto
  • Jan Albert; Dept of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden. Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sto
  • Morten Nielsen; Department of Health Technology, Technical University of Denmark, DK-2800 Lyngby, Denmark. Instituto de Investigaciones Biotecnologicas, Universidad Nacional de
  • Jonas Klingstrom; Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Sara Gredmark-Russ; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. Division of Infectiou
  • Niklas K Bjorkstrom; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Johan K Sandberg; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • David A Price; Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, UK. Systems Immunity Research Institute, Cardi
  • Hans-Gustaf Ljunggren; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Soo Aleman; Division of Infectious Diseases, Karolinska University Hospital and Department of Medicine Huddinge, Stockholm, Sweden.
  • Marcus Buggert; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • - Karolinska COVID-19 Study Group;
Preprint em En | PREPRINT-BIORXIV | ID: ppbiorxiv-174888
ABSTRACT
ABSTRACTSARS-CoV-2-specific memory T cells will likely prove critical for long-term immune protection against COVID-19. We systematically mapped the functional and phenotypic landscape of SARS-CoV-2-specific T cell responses in a large cohort of unexposed individuals as well as exposed family members and individuals with acute or convalescent COVID-19. Acute phase SARS-CoV-2-specific T cells displayed a highly activated cytotoxic phenotype that correlated with various clinical markers of disease severity, whereas convalescent phase SARS-CoV-2-specific T cells were polyfunctional and displayed a stem-like memory phenotype. Importantly, SARS-CoV-2-specific T cells were detectable in antibody-seronegative family members and individuals with a history of asymptomatic or mild COVID-19. Our collective dataset shows that SARS-CoV-2 elicits robust memory T cell responses akin to those observed in the context of successful vaccines, suggesting that natural exposure or infection may prevent recurrent episodes of severe COVID-19 also in seronegative individuals.Competing Interest StatementThe authors have declared no competing interest.View Full Text
Licença
cc_no
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Tipo de estudo: Cohort_studies / Observational_studies / Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Tipo de estudo: Cohort_studies / Observational_studies / Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Preprint